For someone who leads the country’s largest pharmaceuticals company, 67-year-old Dilip Shanghvi is painfully low profile. But despite the reluctance to be in the public eye, the reclusive billionaire, who features among the Top 10 richest people in India, has been hard at work to script a dramatic turnaround in fortunes for his company, Sun Pharmaceutical Industries Ltd. Between 2014 and 2018, Shanghvi had been navigating choppy waters. Intense pricing pressures in the US market—where Sun Pharma is a major player—together with regulatory issues and product recalls had been keeping the company’s management on their toes. Besides, its mega acquisition of Ranbaxy Laboratories in 2014 also brought its own set of challenges, especially problems around regulatory compliance, requiring Sun Pharma to improve quality control and manufacturing processes. This apart, the…